Alumis Prices Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 27, 2024 – Alumis Inc. ("Alumis" or the "Company") (Nasdaq: ALMS), a clinical-stage biopharmaceutical firm focused on developing oral therapies for immune-mediated diseases through precision medicine, has announced the pricing of its initial public offering. The company will offer 13,125,000 shares of common stock at a price of $16.00 per share, with all shares being offered by Alumis. The underwriters also have a 30-day option to purchase up to an additional 1,968,750 shares at the same price, excluding underwriting discounts and commissions.

Trading of Alumis' shares is set to begin on Nasdaq on June 28, 2024, under the ticker symbol "ALMS." The offering is predicted to close on July 1, 2024, contingent upon customary closing conditions being met or waived. Morgan Stanley, Leerink Partners, Cantor, and Guggenheim Securities are the joint book-running managers for the offering.

Alongside the public offering, Alumis has agreed to sell an additional 2,500,000 shares of its common stock in a concurrent private placement at $16.00 per share to AyurMaya Capital Management Fund, LP, one of its existing investors. These shares will not be registered under the Securities Act of 1933 and are subject to a 180-day lock-up agreement. The private placement is expected to close shortly after the public offering, on or before July 22, 2024, and is contingent on the closing of the public offering.

The expected gross proceeds from both the public offering and the private placement are anticipated to total approximately $250 million, before deducting underwriting discounts and commissions as well as other expenses related to the offerings. This total does not include any additional revenue from the potential exercise of the underwriters' option to purchase extra shares.

Alumis has filed a registration statement related to the securities being offered, which has become effective as of June 27, 2024. This offering will be made exclusively through the prospectus that forms part of the registration statements. While this announcement does not constitute an offer to sell or solicitation to buy these securities, the registration statement can be accessed on the SEC’s official website.

Alumis is a clinical-stage biopharmaceutical company that leverages its proprietary precision data analytics platform to develop a pipeline of molecules aimed at treating a wide range of immune-mediated diseases. Its lead product candidate, ESK-001, is an oral, highly selective, small molecule allosteric inhibitor of TYK2, in trials for treating moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Another candidate, A-005, is a CNS-penetrant allosteric TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases. Alumis’ approach is grounded in precision medicine, aiming to develop next-generation drug treatments to address immune dysfunction. The company was incubated by Foresite Labs and is managed by a team with extensive experience in small-molecule drug development for immune-mediated conditions.